U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581704) titled 'Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma' on May 05.
Brief Summary: This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Sirolimus
Sirolimus is an immunosuppressant drug. Sirolimus binds to FK binding protein 12 and inhibits mTOR. This then suppresses T-cell proliferation and inhibits progressi...